Company Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Aug 21, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 187 |
| CEO | Dr. Nello Mainolfi M.D., Ph.D. |
Contact Details
Address: 500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 United States | |
| Phone | 857-285-5314 |
| Website | kymeratx.com |
Stock Details
| Ticker Symbol | KYMR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001815442 |
| CUSIP Number | 501575104 |
| ISIN Number | US5015751044 |
| Employer ID | 81-2992166 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder and Chairman |
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Bruce N. Jacobs CFA | Chief Financial Officer |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer |
| Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer |
| Ellen V. Chiniara Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Karen Weisbach | Head of People and Culture |
| Dr. Juliet Williams B.A Ph.D. | Head of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 144 | Filing |
| Mar 15, 2024 | 144 | Filing |
| Mar 14, 2024 | 144 | Filing |